Article

Hyperthermia as an immunotherapy strategy for cancer.

Department of Immunology, Elm & Carlton Streets, Buffalo, NY 14263, USA.
Current opinion in investigational drugs (London, England: 2000) (impact factor: 3.31). 07/2009; 10(6):550-8. pp.550-8
Source: PubMed

ABSTRACT The use of hyperthermia as an adjunct to cancer immunotherapy is supported by an increasing number of research data. Both preclinical and clinical data results have demonstrated improved antitumor immune responses with the addition of mild hyperthermia. The molecular mechanisms responsible for the improved immune reactivity observed in the presence of hyperthermia include the generation of Hsps, the activation of antigen-presenting cells and changes in lymphocyte trafficking. Understanding these hyperthermia-induced processes can serve as the foundation for analyzing current clinical trials, as well as designing future trials in cancer immunotherapy.

0 0
 · 
0 Bookmarks
 · 
30 Views
  • Article: Apoptic renal carcinoma cells are better inducers of cross-presenting activity than their primary necrotic counterpart.
    E D' Hooghe, S Buttiglieri, G Bisignano, D Brusa, G Camussi, L Matera
    [show abstract] [hide abstract]
    ABSTRACT: Vaccination with tumor-loaded dendritic cells (DC) is a promising treatment strategy for patients with renal cell carcinoma (RCC). Cells undergoing cell death proved useful as a source of tumor antigen for DC loading. Both apoptotic and necrotic tumor cells have been shown to efficiently load RCC-tumor antigens on DC. However, no direct comparison of these two kinds of death has been attempted in the same RCC. We compared DC pulsed with apoptotic cells, whole cell lysates or their supernatants of the cell line K1, derived from a patient with clear cell RCC, to determine their ability to activate T cells. Monocyte-derived DCs were pulsed with the different sources of tumor antigen, matured and co-cultured with autologouos peripheral blood lymphocytes. After three weekly re-stimulations with DCs, generation of cytotoxic T lymphocytes CTL was assessed by IFN-gamma release in an ELISpot assay in the presence of the sensitizing target. By comparison with lysate, apoptotic tumor cells induced a higher frequency of MHC class I-restricted IFN-gamma releasing lymphocytes. A higher CTL response was induced by pulsing DCs with cell lysate supernatant compared with whole cell lysate. These results indicate that, although necrotic death has been regarded as highly permissive when compared to apoptotic death, the immunogenicity of the death treatment may vary from one tumor to another.
    International journal of immunopathology and pharmacology 20(4):707-17. · 2.99 Impact Factor
  • Source
    Article: Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.
    Tanja D de Gruijl, Alfons J M van den Eertwegh, Herbert M Pinedo, Rik J Scheper
    [show abstract] [hide abstract]
    ABSTRACT: The field of tumor vaccination is currently undergoing a shift in focus, from individualized tailor-made vaccines to more generally applicable vaccine formulations. Although primarily predicated by financial and logistic considerations, stemming from a growing awareness that clinical development for wide-scale application can only be achieved through backing from major pharmaceutical companies, these new approaches are also supported by a growing knowledge of the intricacies and minutiae of antigen presentation and effector T-cell activation. Here, the development of whole-cell tumor and dendritic cell (DC)-based vaccines from an individualized autologous set-up to a more widely applicable allogeneic approach will be discussed as reflected by translational studies carried out over the past two decades at our laboratories and clinics in the vrije universiteit medical center (VUmc) in Amsterdam, The Netherlands.
    Cancer Immunology and Immunotherapy 10/2008; 57(10):1569-77. · 3.70 Impact Factor
  • Article: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations.
    Y Tamura, P Peng, K Liu, M Daou, P K Srivastava
    [show abstract] [hide abstract]
    ABSTRACT: Immunotherapy of mice with preexisting cancers with heat shock protein preparations derived from autologous cancer resulted in retarded progression of the primary cancer, a reduced metastatic load, and prolongation of life-span. Treatment with heat shock protein preparations derived from cancers other than the autologous cancer did not provide significant protection. Spontaneous cancers (lung cancer and melanoma), chemically induced cancers (fibrosarcoma and colon carcinoma), and an ultraviolet radiation-induced spindle cell carcinoma were tested, and the results support the efficacy of autologous cancer-derived heat shock protein-peptide complexes in immunotherapy of cancers without the need to identify specific tumor antigenic epitopes.
    Science 11/1997; 278(5335):117-20. · 31.20 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

antigen-presenting cells
 
clinical data results
 
future trials
 
Hsps
 
hyperthermia
 
hyperthermia-induced processes
 
increasing number
 
lymphocyte trafficking
 
mild hyperthermia
 
molecular mechanisms responsible